Crossject SA (id:10849 ALCJ)
2.06 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/27/2024 6:37:07 PM)
Exchange closed, opens in 14 hours 22 minutes
-0.48 EUR (-0.48%)
3.00 EUR (3.00%)
-22.26 EUR (-22.26%)
-12.34 EUR (-12.34%)
-52.75 EUR (-52.75%)
-13.08 EUR (-13.08%)
-76.25 EUR (-76.25%)
-78.08 EUR (-78.08%)
About Crossject SA
Market Capitalization 80.16M
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.
| Headquarters (address) |
6 Rue Pauline Kergomard Dijon 21000 France |
| Phone | 33 3 80 54 98 50 |
| Website | https://www.crossject.com |
| Employees | 105 |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Ticker | ALCJ |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 1.52 - 5.96 |
| Market Capitalization | 80.16M |
| P/E trailing | -8.84 |
| P/E forward | 8.85 |
| Price/Sale | 32.10 |
| Beta | 0.848 |
| EPS | -0.250 |
| EPS France (ID:70, base:331) | -1.54 |